Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8624786 | Bone | 2018 | 23 Pages |
Abstract
In ProBone II, a 2-year treatment with ZOL 4â¯mg intravenous every 3â¯months prevented cancer treatment induced bone loss in premenopausal women with breast cancer and maintained the BMD up to 3â¯years post-treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Ioannis Kyvernitakis, Peter Herbert Kann, Friederike Thomasius, Olaf Hars, Peyman Hadji,